Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ 27,327	$ 16,702	$ 65,661	$ 61,110
General and administrative	7,855	6,412	24,171	20,940
Restructuring charges				(63)
Total operating expenses	35,182	23,114	89,832	81,987
Loss from operations	(35,182)	(23,114)	(89,832)	(81,987)
Other income, net:
Interest income	2,328	1,962	7,544	5,822
Interest expense	(82)	(106)	(265)	(339)
Other income, net	211	278	453	825
Total other income, net	2,457	2,134	7,732	6,308
Net loss	$ (32,725)	$ (20,980)	$ (82,100)	$ (75,679)
Net loss per share, basic	$ (0.79)	$ (1.05)	$ (2.04)	$ (3.83)
Net loss per share, diluted	$ (0.79)	$ (1.05)	$ (2.04)	$ (3.83)
Weighted average shares of common stock outstanding, basic	41,443,317	20,059,641	40,182,303	19,767,174
Weighted average shares of common stock outstanding, diluted	41,443,317	20,059,641	40,182,303	19,767,174

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Name:	us-gaap_EarningsPerShareBasic
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.